InterCure Strengthens Position In Cannabis Market With New Private Placement        

Jelena MartinovicBy , Featured Writer
Burn After Reading The 30-second intel for operators and investors

InterCure (Canndoc) secures NIS 22 million ($7.4 million) in committed funding through a private placement at NIS 2.75 per share, with warrants that could lift the total financing to NIS 54 million if fully exercised.

  • Operators: Funds go toward rebuilding and expanding the Nir Oz facility to meet rising demand in Israel and abroad, plus expansion in Germany. Competitors in those markets may face a better-capitalized rival.
  • Investors: Shares were issued above the recent close, with five-year warrants at NIS 4.125, about 53% above the reference price. Existing shareholders and pharma-focused funds participated. Shares traded 23.38% higher at $1.14.
  • Do now: Review the placement terms and warrant structure, then track InterCure's Nir Oz rebuild and German expansion updates to gauge how the capital is deployed.
Short on time? You’re done. Want the numbers?Keep reading ↓

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR), which does business as Canndoc, has obtained NIS 22 million ($7.4 million) in committed funding through a private placement.

What Happened

Under the transaction, the shares are being issued at NIS 2.75 per share, above the recent market closing price of NIS 2.69.

Moreover, investors are to receive warrants exercisable over a five-year period to purchase up to an additional 7,895,143 ordinary shares of the company at NIS 4.125 per share, about 53% above the reference market price.

Why It Matters

The company plans to use the funds to rebuild and expand its Nir Oz facility to meet increasing demand in Israel and international markets, boost global expansion, particularly in Germany, and pursue opportunities emerging from recent U.S. cannabis regulatory changes, CEO Alexander Rabinovich said in a press release.

He called the financing an important step in the company’s recovery and growth strategy.

If investors fully exercise accompanying warrants, the financing could potentially expand to NIS 54 million.

“The participation of certain of our existing shareholders, together with leading pharma-focused investment funds, reflects strong confidence in InterCure’s business model, market position and long-term growth potential,” Rabinovich said in a press release.

What’s Next

With this financing and the expected recovery of war-related damages, InterCure is better positioned to accelerate its recovery, pursue growth opportunities, and achieve sustainable profitability while serving patients, partners, and shareholders, Rabinovich explained.

INCR Price Action

InterCure’s shares traded 23.38% higher at $1.14 per share at the time of writing on Monday.

Related coverage

Image
Jelena Martinovic
June 22, 2026
Covers cannabis news, markets and regulation for IgniteIt. Previously wrote about financial markets for Benzinga and Insider Monkey.
Share: